ENTRY       D02968                      Drug
NAME        Aprepitant (JAN/USP/INN);
            Aponvie (TN);
            Emend (TN);
            Cinvanti (TN)
PRODUCT     APONVIE (Heron Therapeutics)
            CINVANTI (Heron Therapeutics)
            EMEND (Merck Sharp & Dohme LLC)
  GENERIC   APREPITANT (Glenmark Pharmaceuticals)
            APREPITANT (Sandoz)
            APREPITANT (Torrent Pharmaceuticals Limited)
FORMULA     C23H21F7N4O3
EXACT_MASS  534.1502
MOL_WEIGHT  534.4267
CLASS       Gastrointestinal agent
             DG01762  Antiemetic
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG02852  CYP3A/CYP3A4 inhibitor
              DG01522  CYP3A4 inhibitor
            Metabolizing enzyme inducer
             DG02886  CYP2C9 inducer
             DG02853  CYP3A/CYP3A4 inducer
              DG01635  CYP3A4 inducer
REMARK      Same as: C21555
            Therapeutic category: 2391
            ATC code: A04AD12
            Chemical structure group: DG00066
            Product (DG00066): D02968<JP/US> D06597<JP/US>
EFFICACY    Anti-emetic, Antidepressant, Antipsychotic, Neurokinin NK1 antagonist
COMMENT     Antiemetic in chemotherapy-induced emesis, Treatment of psychiatric conditions
TARGET      TACR1 (NK1R) [HSA:6869] [KO:K04222]
  PATHWAY   hsa04080(6869)  Neuroactive ligand-receptor interaction
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION CYP induction: CYP3A4 [HSA:1576], CYP2C9 [HSA:1559]
            CYP inhibition: CYP3A4 [HSA:1576]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A04 ANTIEMETICS AND ANTINAUSEANTS
               A04A ANTIEMETICS AND ANTINAUSEANTS
                A04AD Other antiemetics
                 A04AD12 Aprepitant
                  D02968  Aprepitant (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antiemetics
              Emetogenic Therapy Adjuncts
               Aprepitant
                D02968  Aprepitant (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              23  Digestive organ agents
               239  Miscellaneous
                2391  Antiemetics
                 D02968  Aprepitant (JAN/USP/INN)
            Drug groups [BR:br08330]
             Gastrointestinal agent
              DG01762  Antiemetic
               DG00066  Aprepitant
                D02968  Aprepitant
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00066  Aprepitant
                 D02968  Aprepitant
             Metabolizing enzyme inhibitor
              DG02852  CYP3A/CYP3A4 inhibitor
               DG01522  CYP3A4 inhibitor
                DG00066  Aprepitant
                 D02968  Aprepitant
             Metabolizing enzyme inducer
              DG02886  CYP2C9 inducer
               DG00066  Aprepitant
                D02968  Aprepitant
              DG02853  CYP3A/CYP3A4 inducer
               DG01635  CYP3A4 inducer
                DG00066  Aprepitant
                 D02968  Aprepitant
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Tachykinin
                TACR1 (NK1R)
                 D02968  Aprepitant (JAN/USP/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D02968
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D02968
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D02968
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D02968
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D02968
            Prodrugs [br08324.html]
             D02968
            Drug groups [BR:br08330]
             Gastrointestinal agent
              DG01762  Antiemetic
               DG00066  Aprepitant
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00066  Aprepitant
             Metabolizing enzyme inhibitor
              DG02852  CYP3A/CYP3A4 inhibitor
               DG01522  CYP3A4 inhibitor
                DG00066  Aprepitant
             Metabolizing enzyme inducer
              DG02886  CYP2C9 inducer
               DG00066  Aprepitant
              DG02853  CYP3A/CYP3A4 inducer
               DG01635  CYP3A4 inducer
                DG00066  Aprepitant
DBLINKS     CAS: 170729-80-3
            PubChem: 17397125
            ChEBI: 499361
            PDB-CCD: GBQ
            LigandBox: D02968
            NIKKAJI: J1.059.639D
ATOM        37
            1   C1y C    26.7027  -16.6589
            2   C1y C    25.5120  -17.3466
            3   C8y C    30.2967  -17.3537
            4   C8x C    30.2967  -18.7531
            5   C8y C    31.5086  -19.4529
            6   C8x C    32.7207  -18.7531
            7   C8y C    32.7207  -17.3537
            8   C8x C    31.5086  -16.6539
            9   C1d C    33.9513  -16.6429
            10  C1d C    31.5086  -20.8521
            11  X   F    31.5086  -22.2516
            12  X   F    30.0868  -20.8521
            13  X   F    32.8857  -20.8521
            14  X   F    35.1632  -15.9432
            15  X   F    33.2523  -15.4325
            16  X   F    34.6518  -17.8561
            17  C1c C    29.0848  -16.6539
            18  O2a O    27.8897  -17.3441
            19  C1a C    29.0847  -15.2546
            20  O2x O    26.7025  -15.2593
            21  C1x C    25.4905  -14.5599
            22  C1x C    24.2998  -15.2476
            23  N1y N    24.3000  -16.6470
            24  C8y C    25.5120  -18.7529
            25  C8x C    24.3200  -19.4415
            26  C8x C    24.3203  -20.8409
            27  C8y C    25.5324  -21.5404
            28  C8x C    26.7245  -20.8518
            29  C8x C    26.7242  -19.4524
            30  X   F    25.5326  -22.9515
            31  C1b C    23.0670  -17.3537
            32  C8y C    21.8550  -16.6539
            33  N4x N    21.8548  -15.2314
            34  C8y C    20.5018  -14.7919
            35  N4x N    19.6658  -15.9428
            36  N5x N    20.5020  -17.0936
            37  O5x O    20.0727  -13.4727
BOND        40
            1     1   2 1
            2     3   4 2
            3     4   5 1
            4     5   6 2
            5     6   7 1
            6     7   8 2
            7     3   8 1
            8     7   9 1
            9     5  10 1
            10   10  11 1
            11   10  12 1
            12   10  13 1
            13    9  14 1
            14    9  15 1
            15    9  16 1
            16    3  17 1
            17   17  18 1
            18   17  19 1 #Down
            19    1  18 1 #Down
            20    1  20 1
            21   20  21 1
            22   21  22 1
            23   22  23 1
            24    2  23 1
            25    2  24 1 #Down
            26   24  25 2
            27   25  26 1
            28   26  27 2
            29   27  28 1
            30   28  29 2
            31   24  29 1
            32   27  30 1
            33   23  31 1
            34   31  32 1
            35   32  33 1
            36   33  34 1
            37   34  35 1
            38   35  36 1
            39   32  36 2
            40   34  37 2
///
